Ventyx biosciences announces pipeline updates and highlights strategic priorities at investor r&d day

Phase 2 clinical trials of vtx958 (tyk2 inhibitor) in plaque psoriasis, crohn's disease and psoriatic arthritis are ongoing with topline phase 2 data in plaque psoriasis expected in q4 2023

VTYX Ratings Summary

VTYX Quant Ranking